JPWO2022220227A1 - - Google Patents
Info
- Publication number
- JPWO2022220227A1 JPWO2022220227A1 JP2023514646A JP2023514646A JPWO2022220227A1 JP WO2022220227 A1 JPWO2022220227 A1 JP WO2022220227A1 JP 2023514646 A JP2023514646 A JP 2023514646A JP 2023514646 A JP2023514646 A JP 2023514646A JP WO2022220227 A1 JPWO2022220227 A1 JP WO2022220227A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021068414 | 2021-04-14 | ||
PCT/JP2022/017548 WO2022220227A1 (ja) | 2021-04-14 | 2022-04-12 | テトラヒドロピリドピリミジン化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2022220227A1 true JPWO2022220227A1 (pl) | 2022-10-20 |
Family
ID=83640095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023514646A Pending JPWO2022220227A1 (pl) | 2021-04-14 | 2022-04-12 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2022220227A1 (pl) |
TW (1) | TW202304908A (pl) |
WO (1) | WO2022220227A1 (pl) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2078010B1 (en) * | 2006-12-29 | 2014-01-29 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
US8349838B2 (en) * | 2008-07-09 | 2013-01-08 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
SG172997A1 (en) * | 2009-01-16 | 2011-08-29 | Rigel Pharmaceuticals Inc | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
PL2693881T3 (pl) * | 2011-04-01 | 2020-03-31 | University Of Utah Research Foundation | Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL |
ES2614824T3 (es) * | 2011-11-14 | 2017-06-02 | Ignyta, Inc. | Derivados de uracil como inhibidores de la quinasa axl y c-met |
DK2810937T3 (en) * | 2012-01-31 | 2017-03-13 | Daiichi Sankyo Co Ltd | PYRIDONE DERIVATIVES |
TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
BR112016017897A8 (pt) * | 2014-02-04 | 2020-06-30 | Astellas Pharma Inc | uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação |
TWI723572B (zh) * | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
JP6621477B2 (ja) * | 2014-12-18 | 2019-12-18 | ファイザー・インク | ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用 |
-
2022
- 2022-04-12 TW TW111113796A patent/TW202304908A/zh unknown
- 2022-04-12 WO PCT/JP2022/017548 patent/WO2022220227A1/ja active Application Filing
- 2022-04-12 JP JP2023514646A patent/JPWO2022220227A1/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022220227A1 (ja) | 2022-10-20 |
TW202304908A (zh) | 2023-02-01 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230517 |